
    
      A randomised controlled trial of vinorelbine plus capecitabine versus docetaxel plus
      capecitabine in anthracycline-pretreated women with metastatic breast cancer. The primary
      endpoints of the study is progression free survival (PFS). The secondary endpoints are
      overall response rate (ORR), overall survival (OS) and safety.
    
  